MedTrace Logo

A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer

NCT01611584 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2014-11-13

No results posted yet for this study

Summary

The purpose of this trial is to measure ALA-induced fluorescence in both normal and malignant tissue.

Conditions

  • Lung Cancer in Normal and Malignant Tumors

Interventions

DRUG

ALA-induced Fluorescence

ALA Dose- 20 mg/kg

Sponsors & Collaborators

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Principal Investigators

  • Cherie P Erkmen, MD · Dartmouth-Hitchcock Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01611584 on ClinicalTrials.gov